Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Reviewing the Unmet Needs of Patients with Multiple Sclerosis.
Pharmacology and therapeutic potential of interferons.
Novel therapies for memory cells in autoimmune diseases.
Receptos reports third quarter 2013 financial results
Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration.
Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
Pregnancy outcomes in patients exposed to interferon beta-1b.
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
4th Biannual NeuroUnit Biomarkers for Inflammation and Neurodegeneration Symposium on Biomarkers in Neurodegenerative Disease
Spin-offs: Meet the structure specialists
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana.
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
Federation of Clinical Immunology Societies 2012
Natalizumab treatment during pregnancy - effects on the neonatal immune system.
Fatal Acute Myeloid Leukemia With 11q23 MLL Gene Rearrangement Following Mitoxantrone Treatment in a Case of Childhood-onset Multiple Sclerosis.

Pages